vs
Forafric Global PLC（AFRI）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Forafric Global PLC的季度营收约是再鼎医药的1.3倍（$159.7M vs $127.1M），Forafric Global PLC自由现金流更多（$146.0K vs $-26.7M）
Forafric Global PLC是一家聚焦非洲市场的农业综合企业，业务覆盖农产品生产、加工、分销全价值链，主营谷物、植物油等主食产品，核心市场为北非和西非地区，服务多领域客户，助力区域粮食安全保障。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
AFRI vs ZLAB — 直观对比
营收规模更大
AFRI
是对方的1.3倍
$127.1M
自由现金流更多
AFRI
多$26.8M
$-26.7M
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $159.7M | $127.1M |
| 净利润 | $-12.0M | — |
| 毛利率 | 10.7% | 51.0% |
| 营业利润率 | -2.5% | -54.6% |
| 净利率 | -7.5% | — |
| 营收同比 | — | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AFRIZLAB
| Q4 25 | — | $127.1M | ||
| Q3 25 | — | $115.4M | ||
| Q2 25 | $159.7M | $109.1M | ||
| Q1 25 | — | $105.7M | ||
| Q4 24 | — | $108.5M | ||
| Q3 24 | — | $101.8M | ||
| Q2 24 | $145.6M | $100.1M | ||
| Q1 24 | — | $87.1M |
净利润AFRIZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-36.0M | ||
| Q2 25 | $-12.0M | $-40.7M | ||
| Q1 25 | — | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-41.7M | ||
| Q2 24 | $-8.6M | $-80.3M | ||
| Q1 24 | — | $-53.5M |
毛利率AFRIZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | 10.7% | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | 9.4% | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率AFRIZLAB
| Q4 25 | — | -54.6% | ||
| Q3 25 | — | -42.3% | ||
| Q2 25 | -2.5% | -50.3% | ||
| Q1 25 | — | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | — | -66.6% | ||
| Q2 24 | -0.9% | -76.0% | ||
| Q1 24 | — | -80.7% |
净利率AFRIZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | -31.2% | ||
| Q2 25 | -7.5% | -37.3% | ||
| Q1 25 | — | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -40.9% | ||
| Q2 24 | -5.9% | -80.2% | ||
| Q1 24 | — | -61.4% |
每股收益（稀释后）AFRIZLAB
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.04 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $-0.08 | ||
| Q1 24 | — | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.2M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.3M | $715.5M |
| 总资产 | $246.1M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AFRIZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | $12.2M | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | $16.4M | $630.0M | ||
| Q1 24 | — | $650.8M |
总债务AFRIZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $18.4M | — | ||
| Q1 24 | — | — |
股东权益AFRIZLAB
| Q4 25 | — | $715.5M | ||
| Q3 25 | — | $759.9M | ||
| Q2 25 | $5.3M | $791.7M | ||
| Q1 25 | — | $810.8M | ||
| Q4 24 | — | $840.9M | ||
| Q3 24 | — | $667.7M | ||
| Q2 24 | $16.3M | $704.2M | ||
| Q1 24 | — | $762.2M |
总资产AFRIZLAB
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | $246.1M | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $985.3M | ||
| Q2 24 | $287.1M | $987.4M | ||
| Q1 24 | — | $988.4M |
负债/权益比AFRIZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $706.0K | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $146.0K | $-26.7M |
| 自由现金流率自由现金流/营收 | 0.1% | -21.0% |
| 资本支出强度资本支出/营收 | 0.4% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流AFRIZLAB
| Q4 25 | — | $-26.0M | ||
| Q3 25 | — | $-32.0M | ||
| Q2 25 | $706.0K | $-31.0M | ||
| Q1 25 | — | $-61.7M | ||
| Q4 24 | — | $-55.8M | ||
| Q3 24 | — | $-26.8M | ||
| Q2 24 | $10.5M | $-42.2M | ||
| Q1 24 | — | $-90.1M |
自由现金流AFRIZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | $146.0K | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | $6.4M | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率AFRIZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | 0.1% | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | 4.4% | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度AFRIZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | 0.4% | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | 2.8% | 0.7% | ||
| Q1 24 | — | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AFRI
| Sales to external customers, Total | $159.7M | 100% |
| Couscous & Pasta | $934.0K | 1% |
| Soft Wheat | $393.0K | 0% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
